Health Robotics expands CytoCare market into Spain and Portugal

26 July 2010

Health Robotics has announced it has granted exclusive rights to Grifols S.A. to distribute its CytoCare chemotherapy system in Spain and Portugal, and signed an agreement to to install the first-ever Cancer Therapy Robot in Spain at Vall d'Hebron University Hospital in Barcelona in November 2010.

"We are very excited to have been selected by Health Robotics as their long-term exclusive CytoCare partner in Spain and Portugal, adding the Cancer Therapy Robot in our core Iberian peninsula market to our prior i.v.STATION distribution rights.

Xavier Guix, Vice President of Marketing for Grifols' Hospital System Division, said, "CytoCare, the world's first and only robotic system designed for the safe and sterile preparation of patient-specific hazardous IV Admixtures, represents an ideal complement to our other market-leading Pharmacy Automation products. Vall d'Hebron University Hospital has demonstrated a long trajectory of innovation, utilizing new technologies to achieve excellent peer-reviewed and published efficiency and medication safety results, with prestigious awards such as Best European Pharmacy Management, ESADE's Management Innovation, and finally the Best Health Care Ideas in 2009."

Health Robotics' CEO Werner Rainer said, "It is very exciting to expand our i.v.STATION relationship at such a prestigious hospital as Vall d'Hebron University Hospital, with its world-renowned cancer research program and the well-documented scientific publications by Dr. Josep Monterde and his team of scientists and pharmacists.

We feel rewarded with this new contract after 1,000 Bed Bolzano General Hospital hosted an inspection team from Vall d'Hebron University Hospital in order to ascertain CytoCare's speed, flexibility, and safety in comparison with other IV Robotics companies, and demonstrating that CytoCare handled 70% of Chemo IV doses within a 4 hour time-window.

"Additionally, Grifols is the perfect fit for CytoCare in Spain and Portugal due to its well-established distribution channels, commitment to patient safety, its company stability and superior market footprint, and finally its world-class service infrastructure. In addition to the obvious success in expanding our partnership with Grifols and receiving a repeat endorsement from an existing Health Robotics' partner, I'm very pleased that this new contract symbolizes the first CytoCare installation in Spain, and the eight European Union member country to embrace CytoCare for its Oncology Therapy Compounding needs."

To top